All this promising science, but the stock’s flatlining like a patient in a waiting room. 📉 The news is a firehose of data and deals, yet the price is stuck, volume is anemic, and the RSI is just… meh. The 9-period EMA is slipping under the 21—not a good look. Until this clinical chatter translates to real trading energy, it’s a HOLD. All sizzle, no steak right now. #WaitingForTheSpark

ZyVersa's pipeline is exploding with legit science! 📈 Yet the stock is stuck in neutral, trading sideways with an RSI around 48. The chart shows consolidation, but the news is screaming "undervalued." This is a classic story vs. stats setup. I'm buying the story. This feels like a coiled spring. #BUY

"ZyVersa’s pipeline is popping like a champagne cork! 🍾 FDA nods, $10M funding, and a flood of promising data—this stock’s gone parabolic. RSI at 83? Overbought, sure, but that volume (124M+ shares!) screams FOMO. Chart’s a rocket from $0.70 to $1.47 in a day—classic “holy cow” breakout. News trumps the technicals here: BUY the hype (but maybe keep a finger near the sell button). #BiotechBoom"

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZyVersa Therapeutics, Inc. ZVSA: 0.205 USD

Bullish views

Bearish views